X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
index medicus (24) 24
hematology (13) 13
male (13) 13
female (12) 12
oncology (11) 11
adult (10) 10
hematology, oncology and palliative medicine (10) 10
middle aged (10) 10
transplantation (10) 10
aged (8) 8
clinical trials (7) 7
multiple myeloma (7) 7
patients (7) 7
sensitivity and specificity (7) 7
treatment outcome (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer (6) 6
leukemia (6) 6
pcr (6) 6
therapy (6) 6
transplants & implants (6) 6
cells, cultured (5) 5
chemotherapy (5) 5
disease-free survival (5) 5
health aspects (5) 5
immunology (5) 5
multiple myeloma - drug therapy (5) 5
reproducibility of results (5) 5
stem-cell transplantation (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
blood (4) 4
bone-marrow-transplantation (4) 4
bortezomib (4) 4
care and treatment (4) 4
dose-response relationship, drug (4) 4
double-blind method (4) 4
hematopoietic stem cells (4) 4
identification (4) 4
in-vitro (4) 4
infections (4) 4
infectious diseases (4) 4
microbiology (4) 4
multiple myeloma - genetics (4) 4
multiple myeloma - mortality (4) 4
mycology (4) 4
research (4) 4
stem cell transplantation (4) 4
stem cells (4) 4
survival analysis (4) 4
t cells (4) 4
time factors (4) 4
adolescent (3) 3
analysis (3) 3
apoptosis - drug effects (3) 3
aspergillosis - diagnosis (3) 3
aspergillus - genetics (3) 3
aspergillus - isolation & purification (3) 3
bone-marrow (3) 3
cell line, tumor (3) 3
chronic myeloid-leukemia (3) 3
classification (3) 3
conferences and conventions (3) 3
conferences, meetings and seminars (3) 3
cytomegalovirus - immunology (3) 3
disease control (3) 3
disease progression (3) 3
expansion (3) 3
expression (3) 3
further section · weitere sektionen (3) 3
immunosuppressive agents (3) 3
immunotherapy (3) 3
kaplan-meier estimate (3) 3
medicine & public health (3) 3
mortality (3) 3
multicenter (3) 3
multiple myeloma - pathology (3) 3
nk cells (3) 3
oncology, experimental (3) 3
pathogens (3) 3
polymerase chain reaction (3) 3
preemptive therapy (3) 3
protein kinase inhibitors - pharmacology (3) 3
risk (3) 3
transplantation, homologous (3) 3
young adult (3) 3
administration, oral (2) 2
advanced basic science (2) 2
age (2) 2
age factors (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
antiviral agents (2) 2
aspergillosis - microbiology (2) 2
bcr-abl (2) 2
bone marrow (2) 2
capecitabine (2) 2
cell proliferation (2) 2
cell proliferation - drug effects (2) 2
chemoradiation (2) 2
chemotherapy, adjuvant (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 9, pp. 855 - 864
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 4, pp. 284 - 292
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 11, pp. e506 - e515
Summary Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus... 
Hematology, Oncology and Palliative Medicine | MULTICENTER | LBH589 | LENALIDOMIDE | END-POINTS | RISK | OUTCOMES | COMBINATION | HEMATOLOGY | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Fatigue - chemically induced | Multiple Myeloma - ethnology | Bortezomib - pharmacology | Dexamethasone - pharmacology | Time Factors | Renal Insufficiency - complications | Panobinostat | Patient Dropouts - statistics & numerical data | Thrombocytopenia - chemically induced | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Dexamethasone - therapeutic use | Geography - statistics & numerical data | Indoles - adverse effects | Bortezomib - therapeutic use | Bortezomib - adverse effects | Survival Analysis | Creatinine - blood | Quality of Life | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Age Factors | Multiple Myeloma - mortality | Hydroxamic Acids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Diarrhea - chemically induced | Neoplasm Recurrence, Local - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Multiple Myeloma - drug therapy | Chromosome Aberrations - statistics & numerical data | Chromosome Aberrations - drug effects | Adult | Female | Indoles - pharmacology | Steroids - therapeutic use | Hydroxamic Acids - pharmacology | Double-Blind Method | Blood Cell Count - statistics & numerical data | Multiple Myeloma - complications | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Treatment Outcome | Asthenia - chemically induced | Hydroxamic Acids - pharmacokinetics | Asian Continental Ancestry Group - ethnology | Disease-Free Survival | Activities of Daily Living - classification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Indoles - pharmacokinetics | Aged | Neoplasm Staging | Bortezomib - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | Immunologic Factors - therapeutic use
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 679 - 687
Journal Article